Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome

Overview

The investigators developed an easy identification model to identify metabolic syndrome in patients with schizophrenia or schizoaffective disorder who received treatment of clozapine, olanzapine, or risperidone. The accuracy of the investigators' models showed well. In the study, the investigators aim to (1) to examine whether the developed identification models can be generalized to patients taking other antipsychotics or patients with other diagnoses; (2) to develop an easy risk score and validate it; (3) to switch antipsychotics to amisulpride or aripiprazole for those with metabolic syndrome, and compare the changes of metabolic parameters including adiponectin, and analyze their association with genetic variants, demography, and clinical variables; (4) to establish models using artificial neural network and statistic method to predict metabolic response after a switch to amisulpride or aripiprazole; (5) to investigate the effect of antipsychotics on adiponectin gene expression and secretion during the differentiation process of 3T3L1 adipocytes.

Full Title of Study: “Easy Identification, Treatment Response Prediction, and Molecular Mechanism Exploration of Antipsychotic-related Metabolic Syndrome”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: August 2012

Interventions

  • Drug: amisulpride
    • Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
  • Drug: aripiprazole
    • Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.

Arms, Groups and Cohorts

  • Experimental: Amisulpride
    • A slow plateau cross-titration method was used to switch original antipsychotics to Amisulpride.
  • Experimental: Aripiprazole
    • A slow plateau cross-titration method was used to switch original antipsychotics to Aripiprazole.

Clinical Trial Outcome Measures

Primary Measures

  • Metabolic profile
    • Time Frame: half/one year

Secondary Measures

  • Clinical efficacy
    • Time Frame: half/one year

Participating in This Clinical Trial

Stage I for identification of metabolic syndrome: Inclusion Criteria:

  • A diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, mood disorders, or anxiety disorders based on DSM-IV-TR criteria. – Age at least 20 years old. – The current antipsychotic drugs have been used for at least 3 months before evaluation. – Psychiatrically stable with Clinical Global Impression of Severity scale (CGI-S) not greater than 5 Exclusion Criteria:

  • Severe uncontrolled medical illnesses, including cardiovascular, hepatic, renal and metabolic diseases (eg. cancer, poor-control hypertension, diabetes mellitus, and other metabolic diseases). – Organic mental or neurological disorder, substance abuse or dependence (alcohol, amphetamine, heroin). – Pregnant or breast-feeding women. – Patients from Yuli Veterans Hospital, who attended our previous study of identification model. Stage II for switch response: Inclusion Criteria:

  • The same as Stage I criteria. – Fulfill the metabolic syndrome criteria. Exclusion Criteria:

  • The same as Stage I criteria except the 4th item. – Treated with depot form of antipsychotics.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National Taiwan University Hospital
  • Collaborator
    • Yu-Li Veterans Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Chao-Cheng Lin, M.D.,Ph.D., Principal Investigator, National Taiwan University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.